Amylyx May Withdraw ALS Drug After Study Fail

Published on March 8, 2024

Amylyx Pharmaceuticals is considering withdrawing its treatment for amyotrophic lateral sclerosis from the market after the drug failed to slow disease progression in a late-stage trial, sending its shares crashing 85% on Friday. The company said it would stop promotions of…

Read Full Article (External Site)